e-1. subjects with a history of seizures, encephalopathy or psychosis, e-2. subjects who have a known allergy to any vaccine or are allergic to any component of the vaccine to be administered, e-3. pregnant or lactating women, women who have a positive pregnancy test or plan to become pregnant within the next 6 months. e-4. subjects whose body temperature is above 37.2oc at the time of vaccination or who have signs of active infection, e-5. subjects with a positive history of sars (sars-cov-1) (based on voluntary declaration), e-6.subjects with severe cardiovascular disease (arrhythmia, conduction block, myocardial infarction, uncontrolled hypertension), e-7. subjects with serious chronic diseases (asthma, diabetes, thyroid diseases, etc.), e-8. subjects with congenital or acquired angioedema, e-9. subjects with a diagnosis of immunodeficiency, e-10. subjects with a diagnosis of bleeding diathesis, e-11. subjects who take immunosuppressive treatment, those who take anti-allergic treatment, those who take cytotoxic treatment, those who take inhaled corticosteroids (except for allergic rhinitis or topical steroid ointments), e-12. subjects who received blood and blood product transfusion in the last 4 months, e-13. subjects who participated in any vaccine study or took experimental drugs within 1 month before starting the study, e-14. subjects who received any live vaccines in the 1 month prior to the study e-15. subjects who received inactivated vaccine within 14 days of starting the study e-16. subjects receiving active tuberculosis treatment, e-17. subjects with a personal or family history of thrombosis and thromboembolism, persons prone to thrombosis e-18. according to the researcher's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the volunteer's compliance with the study will be excluded from the study.

e-1. subjects with a history of seizures, encephalopathy or psychosis, e-2. subjects who have a known allergy to any vaccine or are allergic to any component of the vaccine to be administered, e-3. pregnant or lactating women, women who have a positive pregnancy test or plan to become pregnant within the next 6 months. e-4. subjects whose body temperature is above 37.2oc at the time of vaccination or who have signs of active infection, e-5. subjects with a positive history of sars (sars-cov-1) (based on voluntary declaration), e-6.subjects with severe cardiovascular disease (arrhythmia, conduction block, myocardial infarction, uncontrolled hypertension), e-7. subjects with serious chronic diseases (asthma, diabetes, thyroid diseases, etc.), e-8. subjects with congenital or acquired angioedema, e-9. subjects with a diagnosis of immunodeficiency, e-10. subjects with a diagnosis of bleeding diathesis, e-11. subjects who take immunosuppressive treatment, those who take anti-allergic treatment, those who take cytotoxic treatment, those who take inhaled corticosteroids (except for allergic rhinitis or topical steroid ointments), e-12. subjects who received blood and blood product transfusion in the last 4 months, e-13. subjects who participated in any vaccine study or took experimental drugs within 1 month before starting the study, e-14. subjects who received any live vaccines in the 1 month prior to the study e-15. subjects who received inactivated vaccine within 14 days of starting the study e-16. subjects receiving active tuberculosis treatment, e-17. subjects with a personal or family history of thrombosis and thromboembolism, persons prone to thrombosis e-18. according to the researcher's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the volunteer's compliance with the study will be excluded from the study.